Plazomicin - Cipla
Alternative Names: [14C]-plazomicin; ACHN-490; Plazomicin sulfate; ZEMDRILatest Information Update: 28 Feb 2024
Price :
$50 *
At a glance
- Originator Isis Pharmaceuticals
- Developer Cipla USA
- Class Aminoglycosides; Antibacterials; Small molecules
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Pyelonephritis; Urinary tract infections
- Preregistration Bacteraemia; Nosocomial pneumonia
- No development reported Gram-negative infections; Renal failure; Respiratory tract infections; Tularaemia; Yersinia infections
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Renal-failure in USA (IV, Infusion)
- 26 Feb 2024 Registered for Urinary tract infections (Complicated) in India (IV), prior to February 2024
- 26 Feb 2024 Registered for Pyelonephritis in India (IV), prior to February 2024